No images? Click here

Newsletter banner with RSV and IDCRC logo

IDCRC Newsletter: December 2025

Season's greeting from the IDCRC leadership group (photos of Drs. Stephens, Campbell, and Dionne)

As 2025 comes to a close, the IDCRC Leadership Group would like to extend their gratitude for your efforts and dedication this year. We wish our network and partners a happy and safe holiday season. We will see you in 2026!

“Wishing everyone a wonderful holiday season with friends and family. I want to thank you for your tremendous contributions to the goals and studies of the IDCRC over the last year.”—David Stephens, MD, IDCRC PI and LG chair (pictured left)

 
Photo of Dr. Stephens, Dr. Campbell, and Dr. Dionne

"With the winter holidays and the end of 2025 approaching, I want to thank everyone for your hard work and enthusiasm this year. It is my sincere pleasure to work with all of you. May you and your families have a wonderful holiday season!"—Jim Campbell, MD, MS, LG vice chair (pictured middle)

"As a tumultuous year comes to an end, I am grateful to all of the dedicated colleagues who make our IDCRC network such a terrific team. Thank you for your ongoing support for the science and our study participants."—Jodie Dionne, MD, MSPH, LOC director (pictured right)

 

IDCRC Spotlight: PROMISE Study
Site Principal Investigator, Rebecca C. Brady, MD

Headshot of Rebecca Brady

This month's IDCRC investigator spotlight features Rebecca C. Brady, MD, (Cincinnati Children's Hospital Medical Center), site principal investigator for the PROMISE study. This study is evaluating the effects of maternal vaccination and infant monoclonal antibody administration on RSV antibody levels in mothers and infants, providing essential insights into how these interventions function independently and in combination.

"One strength of the IDCRC is that it works together efficiently and quickly to establish the safety and protective efficacy of vaccines against pathogens that are important public health threats. A second strength is the mentoring of junior investigators by senior vaccinologists."

READ DR. BRADY'S FULL SPOTLIGHT
 

Help us commit to our New Year's resolution!

As we wrap up a great 2025, we want to start the new year strong. Help us with our resolution to spotlight YOU in the upcoming year. With our expansive network of investigators, staff, and administrative team members, we know you have great news and updates that deserve some attention.

Not sure what to submit? Below are a few ideas...

  • Have you or a team member received an award recently? 
  • Did you present your research at a conference? Have you recently delivered a lecture?
  • Do you know an investigator who was recently featured in the media?
  • Do you know someone who is doing excellent work and deserves a shoutout to the network?
  • Do you want to promote an event, a job opening on your team, or a research opportunity at your institution?

If you answered YES to any of the questions above or have another idea in mind for a future IDCRC newsletter, contact our team!

SHARE YOUR NEWS HERE
 

Publications

NOTE: Please include the following citation in any publications resulting from direct or indirect IDCRC support: 

"Supported by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases of the National Institutes of Health, under award number UM1AI148684. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."

 

View recent IDCRC Publications:

  • Intestinal organoid models as tools to interrogate the physiology of human mucosal tissues and host-microbe interactions
  • Safety and immunogenicity of the Sm-p80 GLA-SE schistosomiasis vaccine
VIEW FULL ARCHIVE
 

Training

IDCRC Mentee Profile: Sabiha Rabia Hussain, MD

Sabiha Rabia Hussain, MD headshot

Sabiha Rabia Hussain, MD, is a third-year pediatric infectious diseases fellow at Texas Children's Hospital/Baylor College of Medicine. Her research focuses on the nasal microbiota of preterm infants prior to NICU discharge and during acute respiratory viral infections.

Dr. Hussain is a member of the IDCRC's Mentorship Program cohort. This program provides mentoring and development opportunities for early-career investigators and fellows in clinical and translational infectious diseases research.

"I love learning from experts in clinical research design and writing. For example, we spoke with an editor from JAMA, and her advice was incredibly helpful!"

READ HER FULL SPOTLIGHT HERE
 

News

Medscape | Real-World Data for Nirsevimab, Maternal RSV Vaccine Show Sizeable Drop in Infant Hospitalizations

In the first respiratory syncytial virus (RSV) season with widespread availability of two preventive options against the virus, RSV-related hospitalizations of young infants declined substantially, and both products showed real-world effectiveness similar to what was seen in clinical trials, according to two studies presented at the Infectious Disease Week (IDWeek) 2025 Annual Meeting in Atlanta.

 
Person receiving vaccine

The data came from the New Vaccine Surveillance Network (NVSN), which prospectively enrolls children younger than 18 years old who have an emergency, outpatient, or inpatient visit for acute respiratory illness at one of the seven included sites in Rochester, Pittsburgh, Cincinnati, Nashville, Kansas City, Houston, and Seattle. The researchers analyzed trends from infants less than 6 months old who had a positive RSV PCR test, including those with other viral coinfections.

READ FULL ARTICLE HERE
 

IDSA | A View from the Trenches: Critical Information for Respiratory Virus Season with C. Buddy Creech, MD, MPH

The IDSA's Congressional Briefing recording, "A View from the Trenches: Critical Information for Respiratory Virus Season," features physician speakers, including C. Buddy Creech, MD, MPH, Vanderbilt VTEU PI. Together, they discuss how their institutions are preparing for respiratory virus season, including predictions and vaccination recommendations. 

IDSA Congressional Briefing: A View from the Trenches: Critical Information for Respiratory Virus Season
WATCH THE FULL BRIEFING HERE
 

NBC News | Norovirus is spreading earlier again this year, wastewater data shows with Robert Atmar, MD

For over 30 years, norovirus outbreaks have been dominated by one strain, GII.4. Last year’s outbreaks were overwhelmingly caused by the variant GII.17, making up around 75% of outbreaks. The GII.17 strain has become more prevalent in several countries, including the United States, through the 2020s. The rise of GII.17 may explain why the 2024 spikes and this year’s spread started earlier in October, instead of winter.

Dr. Robert Atmar, professor in the Department of Medicine at Baylor College of Medicine, said a combination of factors may have led to GII.17’s dominance. “The two possibilities are that something in the virus changed to make it more transmissible, or there were changes in the population that a larger proportion were susceptible,” he said. “And probably it’s a combination of both. But whether it’s going to persist this year, I think, is one of the big questions in our scientific community.”

READ FULL ARTICLE HERE
 

Georgia Trend | Carlos del Rio, MD, MACP, named one of
Georgia's Most Influential Leaders in Healthcare

Congratulations to Carlos del Rio, MD, MACP, Emory Vaccine Center VTEU co-PI, on being named one of Georgia Trend's 500 Most Influential Leaders in Healthcare. He receives this recognition for his decades of patient care, infectious disease and global health research, medical education, and healthcare administration.

Headshot of Carlos del Rio
VIEW RECOGNITION
 

Job Postings

Newly Posted! Infectious Diseases Research Job Openings

  • Fred Hutch - Post-Doctoral Research Fellow 
  • Gates Foundation - Senior Program Officer, Vaccine Discovery 

  • Medical University of South Carolina  -  Research Program Coordinator II - Department of Medicine: Division of Infectious Diseases 

  • NYU Langone Health - Infectious Diseases Clinician Educator 

  • Virginia Commonwealth University School of Medicine - Post-Doctoral Fellow - Department of Microbiology and Immunology, School of Medicine 

  • University of Rhode Island - Assistant Professor in Microbiology and Infectious Diseases 

Visit the IDSA Career Center to browse other ID/HIV Medicine job postings.

 

Funding Opportunities

2026 Deadline: 

Georgia CTSA TL1 (T32-like) Clinical and Translational Research Training Program 
Deadline: Tuesday, February 17, 2026

Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)  
Deadline: Wednesday, February 18, 2026

Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed) *NEW*
Deadline: May 15, 2026  

Notice of Special Interest (NOSI): Using Targeted Degradation of Protein and non-Protein Targets for the Development of Novel Anti-Infectives
Deadline: Friday, July 17, 2026

Notice of Special Interest (NOSI): Promoting Research and Development of Vaccines Against Enteric Viruses  
Deadline: Friday, July 17, 2026

Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)  
Deadline: Friday, August 7, 2026

2027 Deadline:

Notice of Special Interest (NOSI): Research to Stimulate Development of Diagnostics, Therapeutics, and Vaccines for Herpes Simplex Virus (HSV) 
Deadline: Wednesday, April 6, 2027

Notice of Special Interest (NOSI): Systems Modeling of Infection and Immunity Across Biological Scales 
Deadline: Wednesday, September 8, 2027

Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Universal Influenza Vaccine 
Deadline: Sunday, November 17, 2027

Notice of Special Interest (NOSI): Accelerating Malaria Vaccine and Monoclonal Antibody Discovery 
Deadline: Sunday, November 17, 2027

 

Annual Meeting

Save the Date: 2026 Annual Meeting

Save the date! Next year's IDCRC Annual Meeting will take place on Wednesday, May 13, and Thursday, May 14, 2026. We look forward to seeing everyone then. Stay tuned for more details!

ANNUAL MEETING WEBPAGE
 

IDCRC Studies

Active Studies Recruiting Volunteers

  • A Phase 4 Study of a 3-Day vs. 7-Day Regimen of Doxycycline for the Treatment of Chlamydial Infection (DMID 22-0019)

Fully Enrolled Studies in Follow-up

  • A Randomized, Double-Blind, Placebo-Controlled Phase 1 Trial to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of Sanaria(R) PfSPZ-LARC2 Vaccine, a Late-Arresting, Replication-Competent, Genetically Attenuated Plasmodium Falciparum Vaccine by Controlled Human Malaria Infection in Malaria-Naïve Healthy Adults Conditions (DMID 23-0010)
  • Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults (DMID 23-0006)
  • A Phase 1 Trial to Evaluate the Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine, HydroVax-001B WNV in Healthy Adults (DMID 24-0008)

  • Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine (DMID 22-0020A)

  • A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety and Pharmacokinetics of a Single Ascending Dose of EV-D68-228 in Healthy Adult Volunteers (DMID 23-0005)

  • A Prospective, Randomized, Open-label Phase 4 Study of the Immunology and Safety of Maternal RSV Vaccination (ABRYSVOTM), Infant Nirsevimab (BEYFORTUSTM) Immunization, or Both Products During the First Year of Life (PROMISE) (DMID 24-0003)
IDCRC ACTIVE AND COMPLETED STUDIES
 

IDCRC Concept Quick Stats

ICP Status

  • Approved: 70

  • Administratively Not Supported: 29

  • Not Approved: 77

  • EWG Review: 2

  • EWG Liaisons: 0

  • EMT Concurrence: 0

  • Withdrawn: 23

  • Hold: 0

  • Moved to Active Study: 7

EWG Assignment

  • COVID: 92

  • Respiratory: 50

  • Emerging Infections: 22

  • Enteric Inf.: 12

  • Malaria and Tropical Dis.: 13

  • Sexually Transmitted Infections: 19

  • Mpox: 7

ECP Status

  • EWG Review-In Process: 0

  • EMT Review: 0

  • Approved-moved to Prioritization: 1

  • Not Approved: 29

  • Approved-moved to Protocol development: 2

  • Active Study: 7

  • EMT Vote: 0

  • Study in Protocol Development: 5

  • Study Closed (LSLV Complete): 9

  • Other: 11

IDCRC STUDIES
 

Communication Resources

COMMUNICATION TOOLKIT
 

Please submit IDCRC news to idcrc@emory.edu for inclusion in the monthly newsletter and IDCRC.org.

VISIT IDCRC WEBSITE
NEWSLETTER ARCHIVE
SUBSCRIBE TO NEWSLETTER
 
 
 

Woodruff Health Sciences Center
Emory University
1440 Clifton Road NE
Atlanta, GA 30322, United States

Subscribe

Preferences  |  Unsubscribe